stockrowSarepta Therapeutics, Inc.
SRPT Healthcare Biotechnology
Sarepta Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 15.6% from fiscal 2024.
- Revenue
- −4.51%
- EPS
- +46.0%
- Free cash flow
- +231.8%
- Total debt
- −17.2%
Quarter to September 2026, against a year earlier
Follow SRPT
Alert me
Sarepta Therapeutics, Inc. (SRPT) Total debt
Sarepta Therapeutics, Inc.'s total debt at the end of fiscal 2025 was $829.0M, down 27.1% from $1.1B in fiscal 2024. At the end of the quarter to 30 September 2026 it was $857.4M. Over the past ten years it has ranged from $16.2M (fiscal 2016) to $1.6B (fiscal 2022); the current reading is higher than 55% of that period. Sarepta Therapeutics, Inc. ranks 18th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $829.0M | (27.10%) |
| FY2024 | $1.1B | (8.15%) |
| FY2023 | $1.2B | (20.61%) |
| FY2022 | $1.6B | 40.24% |
| FY2021 | $1.1B | 9.71% |
| FY2020 | $1.0B | 46.90% |
| FY2019 | $689.9M | 64.05% |
| FY2018 | $420.6M | (2.44%) |
| FY2017 | $431.1M | 2,569.05% |
| FY2016 | $16.2M | (22.75%) |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $857.4M | 1.15% |
| Jun 2026 | $847.6M | 1.13% |
| Mar 2026 | $838.2M | 1.11% |
| Dec 2025 | $829.0M | (19.92%) |
| 43 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| SRPT Sarepta Therapeutics, Inc. | $857.4M |
| MRVI Maravai LifeSciences Holdings, Inc. compare | $176.5M |
| HRMY Harmony Biosciences Holdings, Inc. compare | $149.1M |
| VIR Vir Biotechnology, Inc. compare | $128.0M |
| MESO Mesoblast Limited compare | $126.9M |
| REPL Replimune Group, Inc. compare | $121.2M |
| MAZE Maze Therapeutics, Inc. compare | $39.0M |
| TRVI Trevi Therapeutics, Inc. compare | $31.0K |
| TRAX First Tracks Biotherapeutics, Inc. compare | — |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt